Ramírez-Chiquito Josselen Carina, Villegas-Ruíz Vanessa, Medina-Vera Isabel, Sánchez-Cruz Itzel, Frías-Soria Christian Lizette, Caballero Palacios Marcela Concepción, Antonio-Andrés Gabriela, Rubio-Portillo Alejandra Elizabeth, Velasco-Hidalgo Liliana, Perezpeña-Diazconti Mario, Galván-Diaz Cesar Alejandro, López-Santiago Norma Candelaria, Huerta-Yepez Sara, Juárez-Méndez Sergio
Experimental Oncology Laboratory, National Institute of Pediatrics, Mexico City 04530, Mexico.
Postgraduate in Biological Sciences, Postgraduate Unit, Building D, 1st Floor, Postgraduate Circuit, University City, Coyoacán, Mexico City 04510, Mexico.
Int J Mol Sci. 2025 Jan 16;26(2):744. doi: 10.3390/ijms26020744.
Acute lymphoblastic leukemia (ALL) is a malignant neoplasm with the highest incidence in the pediatric population. Although the 5-year overall survival is greater than 85%, in emerging countries such as Mexico, the mortality rate is high. In Mexico, B-ALL is the most common type of childhood cancer; different characteristics suggest the presence of the disease; however, the prognosis is dependent on clinical and laboratory features, and no adverse prognostic molecular marker for B-ALL has yet been identified. The present research aimed to identify the prognostic value of HMMR expression in pediatric patients with B-ALL. The differential expression profile of B-ALL cells was determined via in silico analysis, and HMMR expression was subsequently measured via qRT-PCR and immunocytochemistry. The results were statistically analyzed via the ROUT test, Kolmogorov-Smirnov Z test, and Mann-Whitney U test. ROC curves and the Youden index were constructed, and Kaplan-Meier curves were plotted. We found that HMMR expression was increased in B-ALL patients ( < 0.0001). We observed that high expression was related to poor prognosis ( < 0.05). We observed that high expression was related to poor prognosis ( < 0.05). The increase in HMMR expression could be a potential early molecular prognostic marker and/or a new target in childhood B-ALL patients.
急性淋巴细胞白血病（ALL）是儿科人群中发病率最高的恶性肿瘤。尽管5年总生存率大于85%，但在墨西哥等新兴国家，死亡率仍然很高。在墨西哥，B-ALL是儿童期最常见的癌症类型；不同特征提示疾病的存在；然而，预后取决于临床和实验室特征，且尚未确定B-ALL的不良预后分子标志物。本研究旨在确定HMMR表达在儿童B-ALL患者中的预后价值。通过生物信息学分析确定B-ALL细胞的差异表达谱，随后通过qRT-PCR和免疫细胞化学检测HMMR表达。结果通过ROUT检验、柯尔莫哥洛夫-斯米尔诺夫Z检验和曼-惠特尼U检验进行统计学分析。构建受试者工作特征（ROC）曲线和尤登指数，并绘制Kaplan-Meier曲线。我们发现B-ALL患者中HMMR表达增加（<0.0001）。我们观察到高表达与预后不良相关（<0.05）。我们观察到高表达与预后不良相关（<0.05）。HMMR表达的增加可能是儿童B-ALL患者潜在的早期分子预后标志物和/或新靶点。
